Strategies To Optimize Virtual And Decentralized Study Designs

In the wake of the COVID-19 health crisis, studies need solutions to remediate disruptions and ensure continuity of support for sites and patients participating in research. Understanding how to incorporate technologies and strategies that decrease the reliance upon brick and mortar sites and ‘bring the study to the patient’ for conducting research is critical across all phases of drug development in today’s challenging environment.

Recently, Jersino Jean-Mary, Executive Director, European Late Stage Operations Team, and Aaron Berger, Executive Director, North American Late Stage Operations Team, shared their thoughts on how the pandemic is impacting clinical trials and post-approval research, and ways that the industry is working together to get patients the access they vitally need to novel therapies.